June 24, 2020 • 12 – 1pm EDTRegister for Webinar
Assistant General Counsel and Director for IP Policy
Biotechnology Innovation Organization
Rachel J. Elsby
The novel coronavirus has instigated arguably the most important patent story of the year. As the global pandemic burns forward obstinately, the virus is introducing novel challenges for the biosimilars and innovator biologics industries, including makers of biosimilars.
This informative webinar will analyze the issues pharmaceutical companies are currently facing as they look toward the next phases of the coronavirus response and recovery.
Topics to be discussion will include:
- Analyzing the status of non-COVID therapies?
- Understanding the impact COVID-19 has had on IP licensing and enforcement
- Identifying best practices for IP development
- Assessing the recent changes to IP litigation Anticipating and the potential impact of COVID-19 on IP legal matters, including patent protection for new uses and diagnostics.